Institute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
DZHK (German Center for Cardiovascular Disease), partner site, Goettingen, Germany.
Cardiovasc Res. 2021 Jul 7;117(8):1908-1922. doi: 10.1093/cvr/cvaa239.
Arrhythmias and sudden cardiac death (SCD) occur commonly in patients with heart failure. We found T-box 5 (TBX5) dysregulated in ventricular myocardium from heart failure patients and thus we hypothesized that TBX5 reduction contributes to arrhythmia development in these patients. To understand the underlying mechanisms, we aimed to reveal the ventricular TBX5-dependent transcriptional network and further test the therapeutic potential of TBX5 level normalization in mice with documented arrhythmias.
We used a mouse model of TBX5 conditional deletion in ventricular cardiomyocytes. Ventricular (v) TBX5 loss in mice resulted in mild cardiac dysfunction and arrhythmias and was associated with a high mortality rate (60%) due to SCD. Upon angiotensin stimulation, vTbx5KO mice showed exacerbated cardiac remodelling and dysfunction suggesting a cardioprotective role of TBX5. RNA-sequencing of a ventricular-specific TBX5KO mouse and TBX5 chromatin immunoprecipitation was used to dissect TBX5 transcriptional network in cardiac ventricular tissue. Overall, we identified 47 transcripts expressed under the control of TBX5, which may have contributed to the fatal arrhythmias in vTbx5KO mice. These included transcripts encoding for proteins implicated in cardiac conduction and contraction (Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2), in cytoskeleton organization (Fstl4, Pdlim4, Emilin2, Cmya5), and cardiac protection upon stress (Fhl2, Gpr22, Fgf16). Interestingly, after TBX5 loss and arrhythmia development in vTbx5KO mice, TBX5 protein-level normalization by systemic adeno-associated-virus (AAV) 9 application, re-established TBX5-dependent transcriptome. Consequently, cardiac dysfunction was ameliorated and the propensity of arrhythmia occurrence was reduced.
This study uncovers a novel cardioprotective role of TBX5 in the adult heart and provides preclinical evidence for the therapeutic value of TBX5 protein normalization in the control of arrhythmia.
心律失常和心脏性猝死(SCD)在心力衰竭患者中很常见。我们发现心力衰竭患者的心室心肌中 T 盒转录因子 5(TBX5)失调,因此我们假设 TBX5 的减少有助于这些患者心律失常的发生。为了了解潜在的机制,我们旨在揭示心室 TBX5 依赖性转录网络,并进一步测试 TBX5 水平正常化在有记录心律失常的小鼠中的治疗潜力。
我们使用了心室肌细胞中 TBX5 条件性缺失的小鼠模型。小鼠的心室(v)TBX5 缺失导致轻度心功能障碍和心律失常,并伴有因 SCD 导致的高死亡率(60%)。在血管紧张素刺激下,vTbx5KO 小鼠表现出心脏重构和功能障碍的恶化,表明 TBX5 具有心脏保护作用。对心室特异性 TBX5KO 小鼠的 RNA 测序和 TBX5 染色质免疫沉淀用于解析心脏心室组织中的 TBX5 转录网络。总的来说,我们鉴定了 47 个受 TBX5 控制表达的转录本,这些转录本可能导致 vTbx5KO 小鼠致命性心律失常。这些转录本包括编码与心脏传导和收缩(Gja1、Kcnj5、Kcng2、Cacna1g、Chrm2)、细胞骨架组织(Fstl4、Pdlim4、Emilin2、CmyA5)和应激时心脏保护(Fhl2、Gpr22、Fgf16)相关蛋白的蛋白。有趣的是,在 vTbx5KO 小鼠 TBX5 缺失和心律失常发生后,全身性腺相关病毒(AAV)9 应用使 TBX5 蛋白水平正常化,重新建立了 TBX5 依赖性转录组。因此,心功能障碍得到改善,心律失常发生的倾向降低。
本研究揭示了 TBX5 在成年心脏中的一种新的心脏保护作用,并为 TBX5 蛋白正常化在控制心律失常中的治疗价值提供了临床前证据。